ADAR1 Capital Management LLC Sells 18,368 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

ADAR1 Capital Management LLC decreased its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 81.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,196 shares of the company's stock after selling 18,368 shares during the period. ADAR1 Capital Management LLC's holdings in Disc Medicine were worth $266,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in IRON. Geode Capital Management LLC lifted its holdings in Disc Medicine by 17.6% in the third quarter. Geode Capital Management LLC now owns 474,719 shares of the company's stock worth $23,333,000 after buying an additional 70,983 shares during the period. State Street Corp lifted its stake in shares of Disc Medicine by 39.7% in the 3rd quarter. State Street Corp now owns 827,910 shares of the company's stock valued at $40,683,000 after purchasing an additional 235,115 shares during the period. Verition Fund Management LLC bought a new stake in shares of Disc Medicine during the third quarter valued at approximately $589,000. Charles Schwab Investment Management Inc. grew its stake in Disc Medicine by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 160,554 shares of the company's stock worth $7,890,000 after purchasing an additional 19,401 shares during the period. Finally, Barclays PLC raised its holdings in Disc Medicine by 123.7% in the third quarter. Barclays PLC now owns 40,145 shares of the company's stock worth $1,972,000 after purchasing an additional 22,202 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors.

Remove Ads

Insider Activity

In other Disc Medicine news, Director Mona Ashiya sold 5,738 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $54.11, for a total transaction of $310,483.18. Following the completion of the sale, the director now directly owns 186,541 shares of the company's stock, valued at approximately $10,093,733.51. This represents a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jonathan Yen-Wen Yu sold 1,610 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $87,873.80. Following the completion of the sale, the chief operating officer now owns 40,555 shares of the company's stock, valued at $2,213,491.90. This trade represents a 3.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 361,690 shares of company stock valued at $19,648,094 in the last ninety days. 4.24% of the stock is currently owned by company insiders.

Disc Medicine Trading Up 9.9 %

NASDAQ:IRON traded up $3.50 during mid-day trading on Friday, reaching $38.73. The company's stock had a trading volume of 549,559 shares, compared to its average volume of 346,054. The stock has a market cap of $1.34 billion, a P/E ratio of -9.73 and a beta of 0.77. The firm's fifty day moving average price is $50.88 and its two-hundred day moving average price is $55.57. Disc Medicine, Inc. has a 12-month low of $25.64 and a 12-month high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.08. Analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Morgan Stanley reaffirmed an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. Stifel Nicolaus upped their price objective on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a report on Friday, January 24th. Wedbush reiterated an "outperform" rating and set a $90.00 target price (up from $83.00) on shares of Disc Medicine in a report on Tuesday, January 21st. Cantor Fitzgerald upped their price target on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. Finally, HC Wainwright reiterated a "buy" rating and set a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Disc Medicine presently has an average rating of "Buy" and an average target price of $93.80.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.